Search Medical Condition
Please enter condition
Please choose location from dropdown

Copenhagen OE, Denmark Clinical Trials

A listing of Copenhagen OE, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (748) clinical trials

BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction

This is a multinational, multicentre, randomised open-label, controlled, parallel-group phase III study. Its aim is to demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells is safe and reduces all-cause mortality in patients with reduced left ventricular ejection fraction(</=45%) after successful reperfusion for acute myocardial infarction when ...

Phase

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »

International Guillain-Barr Syndrome Outcome Study

GBS is a post-infectious immune-mediated polyradiculoneuropathy with a highly diverse clinical course and outcome despite partially effective forms of treatment(immunoglobulins and plasma exchange). Outcome in patients with GBS has not improved in the last two decades. At present about 10 to 20% of patients remain severely disabled and about 5% ...

Phase N/A

0.0 miles

Learn More »

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Name of investigational treatment: Influenza vaccine (VaxigripTetra, Sanofi Pasteur MSD). Title of study: Influenza vaccination After Myocardial Infarction (IAMI trial). Study centers: Up to 35 centers in Sweden, Denmark, Norway, Scotland, Czech Rebublic, Latvia and Bangladesh. Planned study period: 2016 - 2020 (influenza season). Long-term follow up to 2025 via ...

Phase

0.0 miles

Learn More »

The Neuro Zti Cochlear Implant System Efficacy and Safety in Adults

The new cochlear implant system is indicated in individuals with serious hearing disabilities who do not obtain benefit from appropriately fitted hearing aid(s). Cochlear implant surgery is safe, but as with any surgery, possible issues or device related issues may occur. The risk benefit balance is well known in cochlear ...

Phase N/A

0.0 miles

Learn More »

CardioMEMS HF System OUS Post Market Study

The purpose of this Post Market Study (PMS) is to evaluate the use of the CardioMEMS HF System in patients with Class III Heart Failure in a commercial setting.

Phase N/A

0.0 miles

Learn More »

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase

0.0 miles

Learn More »

Neurovascular Product Surveillance Registry

An observational, prospective, multi-center, single-arm registry to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic Neurovascular market-released products used in the treatment of Intracranial aneurysms.

Phase N/A

0.0 miles

Learn More »

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), ...

Phase

0.0 miles

Learn More »

REDUCE LAP-HF TRIAL II

Following supine bicycle exercise testing to assess eligibility, the eligible patients are randomized to the treatment or control group. All patients will be sedated, and both treatment and control arm patients will undergo placement of a femoral venous access sheath after randomization. Patients randomized to the treatment arm will undergo ...

Phase N/A

0.0 miles

Learn More »